Cadian Capital Management LP Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Cadian Capital Management LP acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 400,000 shares of the medical research company's stock, valued at approximately $78,604,000. IQVIA accounts for 4.5% of Cadian Capital Management LP's holdings, making the stock its 9th largest position. Cadian Capital Management LP owned approximately 0.22% of IQVIA as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Tidal Investments LLC boosted its holdings in shares of IQVIA by 9.3% during the third quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company's stock worth $1,417,000 after purchasing an additional 509 shares during the period. Franklin Resources Inc. raised its holdings in shares of IQVIA by 1.2% during the third quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company's stock valued at $117,031,000 after acquiring an additional 6,011 shares in the last quarter. Principal Financial Group Inc. lifted its stake in IQVIA by 0.8% in the third quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company's stock worth $49,532,000 after acquiring an additional 1,750 shares during the period. JPMorgan Chase & Co. boosted its holdings in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQV traded down $4.39 during trading on Friday, reaching $148.90. 1,677,229 shares of the company traded hands, compared to its average volume of 1,469,448. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88. The firm has a fifty day simple moving average of $163.91 and a 200 day simple moving average of $188.25. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $25.76 billion, a P/E ratio of 19.85, a PEG ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the business posted $2.54 earnings per share. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on IQV shares. Mizuho dropped their target price on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Citigroup cut their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Morgan Stanley increased their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, StockNews.com downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $231.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.